Hepatic triglyceride biosynthesis in humans with different insulin resistance phenotypes

Hepatic triglyceride biosynthesis in humans with different insulin resistance phenotypes - TRISYNTH

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53815

Enrollment

110

Registered

2023-09-14

Start date

2023-11-16

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Ability to give informed consent; - Age 18-65y; - Overweight or class 1 obesity, defined as BMI 25-35 kg/m2; - Modest hypertriglyceridemia, defined as fasting plasma triglycerides 1.3-3.0mM; - High risk of insulin resistance, defined as fasting plasma insulin >64pM; - Stable weight for at least 3mo prior to participation.

Exclusion criteria

Exclusion criteria: - Active or chronic liver disease, kidney disease, congestive heart failure, unstable angina, history of acute cardiovascular events within 6mo of screening, history of seizures or syncope, or an active infection requiring antimicrobial therapy; - Use of insulin, thiazolidinediones, GLP1 agonists, SGLT2 inhibitors, or sulfonylureas; - Use of fibrates, omega 3 (fish oil), niacin, or PCSK9 antagonists; - Use of systemic glucocorticoids within 60d prior to participation; - Hematocrit 14U/wk), or history of drug abuse.

Design outcomes

Primary

Measure	Time frame
Difference in %DNL between subjects with global vs muscle-only insulin resistance as well as the differential effects of premeal exercise on %DNL in these groups.	—

Secondary

Measure	Time frame
Associations between plasma markers, metabolites, and increased lipogenesis in humans with insulin resistance.	—

Countries

Netherlands

Outcome results